This site is currently implementing core features and is not ready for patient use yet.
This site is currently implementing core features and is not ready for patient use yet.
NanoVax intranasal vaccine platform
BlueWillow Biologics, established as NanoBio in 2000, develops intranasal vaccines using the NanoVax platform for respiratory and sexually transmitted infections, advancing candidates into clinical trials.
No data available
No FAQ items available.